Institute of Molecular Oncology and Stem Cell Biology, Ulm University Hospital, Ulm, Germany.
Institute of Human Genetics, Ulm University & Ulm University Hospital, Ulm, Germany.
J Pathol. 2023 Oct;261(2):139-155. doi: 10.1002/path.6156. Epub 2023 Aug 9.
Within the pancreas, Keratin 19 (KRT19) labels the ductal lineage and is a determinant of pancreatic ductal adenocarcinoma (PDAC). To investigate KRT19 expression dynamics, we developed a human pluripotent stem cell (PSC)-based KRT19-mCherry reporter system in different genetic backgrounds to monitor KRT19 expression from its endogenous gene locus. A differentiation protocol to generate mature pancreatic duct-like organoids was applied. While KRT19/mCherry expression became evident at the early endoderm stage, mCherry signal was present in nearly all cells at the pancreatic endoderm (PE) and pancreatic progenitor (PP) stages. Interestingly, despite homogenous KRT19 expression, mCherry positivity dropped to 50% after ductal maturation, indicating a permanent switch from biallelic to monoallelic expression. DNA methylation profiling separated the distinct differentiation intermediates, with site-specific DNA methylation patterns occurring at the KRT19 locus during ductal maturation. Accordingly, the monoallelic switch was partially reverted upon treatment with a DNA-methyltransferase inhibitor. In human PDAC cohorts, high KRT19 levels correlate with low locus methylation and decreased survival. At the same time, activation of oncogenic KRAS signalling in our reporter system reversed monoallelic back to biallelic KRT19 expression in pancreatic duct-like organoids. Allelic reactivation was also detected in single-cell transcriptomes of human PDACs, which further revealed a positive correlation between KRT19 and KRAS expression. Accordingly, KRAS mutant PDACs had higher KRT19 mRNA but lower KRT19 gene locus DNA methylation than wildtype counterparts. KRT19 protein was additionally detected in plasma of PDAC patients, with higher concentrations correlating with shorter progression-free survival in gemcitabine/nabPaclitaxel-treated and opposing trends in FOLFIRINOX-treated patients. Apart from being an important pancreatic ductal lineage marker, KRT19 appears tightly controlled via a switch from biallelic to monoallelic expression during ductal lineage entry and is aberrantly expressed after oncogenic KRAS expression, indicating a role in PDAC development and malignancy. Soluble KRT19 might serve as a relevant biomarker to stratify treatment. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
在胰腺中,角蛋白 19(KRT19)标记导管谱系,是胰腺导管腺癌(PDAC)的决定因素。为了研究 KRT19 的表达动态,我们在不同的遗传背景下开发了一种基于人多能干细胞(PSC)的 KRT19-mCherry 报告系统,以从其内源基因座监测 KRT19 的表达。应用了一种生成成熟胰腺导管样类器官的分化方案。虽然 KRT19/mCherry 表达在早期内胚层阶段明显,但在胰腺内胚层(PE)和胰腺祖细胞(PP)阶段,mCherry 信号几乎存在于所有细胞中。有趣的是,尽管 KRT19 表达均匀,但在导管成熟后,mCherry 阳性率下降到 50%,表明从双等位基因表达到单等位基因表达的永久转换。DNA 甲基化谱分离了不同的分化中间产物,在导管成熟过程中,KRT19 基因座发生了特定于位点的 DNA 甲基化模式。相应地,在用 DNA 甲基转移酶抑制剂处理后,单等位基因开关部分逆转。在人类 PDAC 队列中,高 KRT19 水平与低基因座甲基化和生存率降低相关。同时,我们的报告系统中致癌 KRAS 信号的激活使胰腺导管样类器官中的单等位基因回复到双等位基因 KRT19 表达。在人类 PDAC 的单细胞转录组中也检测到等位基因激活,这进一步表明 KRT19 与 KRAS 表达之间存在正相关。相应地,KRAS 突变型 PDAC 的 KRT19 mRNA 更高,但野生型对应物的 KRT19 基因座 DNA 甲基化水平更低。KRT19 蛋白也在 PDAC 患者的血浆中检测到,浓度较高与吉西他滨/ nabPaclitaxel 治疗时无进展生存期缩短相关,而在 FOLFIRINOX 治疗时则呈相反趋势。除了作为重要的胰腺导管谱系标记物外,KRT19 似乎在导管谱系进入时通过从双等位基因到单等位基因表达的开关受到严格控制,并且在致癌 KRAS 表达后异常表达,表明其在 PDAC 发展和恶性肿瘤中发挥作用。可溶性 KRT19 可能作为一种相关的生物标志物用于分层治疗。